Clinical Chemistry Link to Randox Laboratories Web Site spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2006.074989v1, 2007; 10.1373/clinchem.2006.074989
This Article
Right arrow Full Text (PDF)
Right arrow 074989.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.074989v1
53/2/251    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sircar and, D.
Right arrow Articles by Subbaiah, P. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sircar and, D.
Right arrow Articles by Subbaiah, P. V.

Received on June 14, 2006
Accepted on November 30, 2006

Lipids, Lipoproteins, and Cardiovascular Risk Factors

Isoprostane Measurement in Plasma and Urine by Liquid Chromatography-Mass Spectrometry with 1-Step Sample Preparation

Debajit Sircar and 1 Papasani V. Subbaiah 2*

1 Departments of Medicine and Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL
2 Department of Medicine and Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, IL

* To whom correspondence should be addressed. E-mail: psubbaiah{at}uic.edu.

Background: Isoprostane F2{alpha} (iPF2{alpha}-III) concentration in plasma and urine is widely accepted as a measure of oxidative stress. Gas chromatography-mass spectroscopy (GC/MS) methods for measuring iPF2{alpha}-III involve several steps of sample preparation and are labor-intensive and ELISA methods, although easier to use, are less reliable. Therefore we developed a simple and sensitive method involving 1-step sample cleanup and HPLC/MS quantification.

Methods: Samples of plasma or urine were enriched with a deuterated (iPF2{alpha}-III-D4) standard, treated with KOH to liberate the bound isoprostanes,then loaded onto an immunoaffinity column, and the bound isoprostane was eluted with 95% ethanol. The concentrated sample was injected onto a C-18 HPLC column, and the isoprostane was eluted with a gradient of acetonitrile in water and analyzed by electrospray negative ionization, selectively monitoring the ions 353.2 (iPF2{alpha}-III) and 357.2 (iPF2{alpha}-III-D4). The amount of isoprostane in the sample was calculated from the ratio of the intensities of the 2 ions.

Results: The described method is highly sensitive (detection limit, 0.5 pg/mL), with a linear dynamic range of 1-5000 pg/mL. The intra- and interassay imprecisions were 4.68% and 3.88%, respectively. The values obtained correlated strongly with the GC/MS procedure (r = 0.80), but the absolute values were ~4-5-fold lower, because the present method measures specifically 1 isomer of isoprostane, whereas the GC/MS method measures 4 isomers together.

Conclusions: Because of its simplicity and sensitivity, the present method provides a useful noninvasive tool for determining oxidative stress in patients.







spacer gif
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2007 by the American Association for Clinical Chemistry.